Prognostic and Therapeutic Indicator of Fluoroboronophenylalanine Positron Emission Tomography in Patients with Gliomas

Clinical Cancer Research

Volumn 9, Issue 16 I, 2003, Pages 5888-5895

  Takahashi, Yoshinobu ^a   Imahori, Yoshio ^a   Mineura, Katsuyoshi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORON 10; BORON DERIVATIVE; CISPLATIN; ETOPOSIDE; FLUORINE 18; FLUOROBORONOPHENYLALANINE; FLUOROBORONOPHENYLALANINE B 10; NITROSOUREA; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; FEMALE; GLIOMA; HISTOLOGY; HUMAN; KAPLAN MEIER METHOD; MALE; NEUTRON CAPTURE THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL TIME;

ADULT; AGED; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; GLIOMA; HUMANS; MALE; MIDDLE AGED; PHENYLALANINE; PROGNOSIS; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0346734284     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Barth, R. F., Soloway, A. H., and Fairchild, R. G. Boron neutron capture therapy of cancer. Cancer Res., 50: 1061-1070, 1990.
2. Coderre, J. A., and Morris, G. M. Review: The radiation biology of boron neutron capture therapy. Radiat. Res., 151: 1-18, 1999.
3. Diaz, A. Z., Coderre, J. A., Chanana, A. D., and Ma, R. Boron neutron capture therapy for malignant gliomas. Ann. Med., 32: 81-85, 2000.
4. 18F]fluorodeoxyglucose and positron emission tomography. Neurology, 32: 1323-1329, 1982.
5. 11C-labeled amino acids. J. Comput. Assist. Tomogr., 6: 544-550, 1982.
6. 18F]fluorodeoxyglucose in brain tumors: a power diagnostic and prognostic tool. Investig. Radiol., 22: 360-371, 1986.
7. 11C]L-methionine uptake in gliomas. Neurosurgery, 25: 720-728, 1989.
8. Coleman, R. E., Hoffman, J. M., Hanson, M. W., Sostman, H. D., and Schold, S. C. Clinical application of PET for the evaluation of brain tumors. J. Nucl. Med., 32: 616-622, 1991.
9. Strauss, L. G., and Conti, P. S. The applications of PET in clinical oncology. J. Nucl. Med., 32: 623-648, 1991.
10. Hanson, M. W., Glantz, M. J., Hoffman, J. M., Friedman, A. H., Burger, P. C., and Schold, S. C. FDG-PET in the selection of brain lesions for biopsy. J. Comput. Assist Tomogr., 15: 796-801, 1991.
11. Levivier, M., Goldman, S., Bidaut, L. M., Luxen, A., Stanus, E., and Przedborski, S. Positron emission tomography-guided stereotactic biopsy. Neurosurgery, 31: 792-797, 1992.
12. Kabalka, G. W., Smith, G. T., Dyke, J. P., Reid, W. S., Longford, C. P. D., Roberts, T. G., Reddy, N. K., and Hubner, K. F. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning and hemodynamic evaluation of gliomas using positron emission tomography. J. Nucl. Med., 38: 1762-1767, 1997.
13. Imahori, Y., Ueda, S., Ohmori, Y., Kusuki, T., Ono, K., Fujii, R., and Ido, T. Fluorine-18-labeled fluoroboronophenylalanine and PET in patients with glioma. J. Nucl. Med., 39: 325-333, 1998.
14. 18F]fluoro-D, L-phenylalanine: a target compound for PET and boron neutron capture therapy. Appl. Radiat. Isot., 42: 325-328, 1991.
15. 18F-DOPA analogue. J. Neurooncol., 33: 163-169, 1997.
16. Mineura, K., Watanabe, K., and Kowada, M. Supratentorial malignant gliomas treated with split course radiotherapy plus chemotherapy of ACNU and FT. Int. J. Oncol., 2: 457-461, 1993.
17. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., and McFadden, E. T. Toxity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5: 649-655, 1982.
18. 15O and positron emission tomography: theory, procedure, and normal values. J. Comput. Assist. Tomogr., 4: 727-736, 1980.
19. Kanno, I., Miura, S., Yamamoto, S., Iida, H., Murakami, M., and Takahashi, K. Design and evaluation of a positron emission tomography: Headtome III. J. Comput. Assist. Tomogr., 9: 931-939, 1985.
20. Sasaki, H., Kanno, I., Murakami, M., Shishido, F., and Uemura, K. Tomographic mapping of kinetic rate constants in the fluorodeoxyglucose model using dynamic positron emission tomography. J. Cereb. Blood Flow. Metab., 6: 447-454, 1986.
21. Phelps, M. E., Huang, S. C., Hoffman, E. J., and Kuhl, D. E. Validation of tomographic measurement of cerebral blood volume with C-11 labeled carboxyhemoglobin. J. Nucl. Med., 20: 328-334, 1979.
22. Kaplan, E. L., and Meier, P. Non parametric estimation for incomplete observations. J. Am. Stat. Assoc., 52: 457-481, 1958.
23. Gehan, E. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika., 52: 203-224, 1956.
24. Cox, D. Regression models and life tables. J. R. Stat. Soc (B)., 34: 187-202, 1972.
25. Yoshino, K., Mori, Y., and Kakihana, H. Chemical modeling with p-boronophenylalanine for boron accumulation to and release from melanoma. In: Y. Mishima, ed. Cancer Neutron Capture Therapy, pp. 81-90. New York: Plenum Press, 1996.
26. Imahori, Y., Ueda, S., Ohmori, Y., Sakae, K., Kusuki, T., Kobayashi, T., Takagaki, M., Ono, K., Ido, T., and Fujii, R. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas. Part I. Clin. Cancer Res., 4: 1825-1832, 1998.
27. Imahori, Y., Ueda, S., Ohmori, Y., Sakae, K., Kusuki, T., Kobayashi, T., Takagaki, M., Ono, K., Ido, T., and Fujii, R. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas. Part II. Clin. Cancer Res., 4: 1833-1841, 1998.
28. Green, S. B., Byar, D. P., Walker, M. D., Pistenmaa, D. A., Alexander, E., and Batzdorf, U. Comparisons of camustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant gliomas. Cancer Treat. Rep., 67: 121-132, 1983.
29. Nelson, J. S., Tsukada, Y., Schoenfeld, D., Fulling, K., Lamarche, J., and Peress, N. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer (Phila.), 52: 550-554, 1983.
30. Murovic, J., Krzystof, T., Wilson, C. B., Hoshino, T., and Levin, V. Computerized tomography in the prognosis of malignant cerebral gliomas. J. Neurosurg., 65: 799-806, 1986.
31. A Report of the Medical Research Council Brain Tumour Working Party. Prognostic factors for high-grade malignant gliomas: development of a prognostic index. J. Neurooncol., 9: 47-55, 1990.
32. 10B-compound. Lancet, 12: 388-389, 1989.
33. Chanana, A. D., Capala, J., Chadha, M., Coderre, J. A., Diaz, A. Z., Elowitz, E. H., Iwai, J., Joel, D. D., Liu, H., Ma, R., Pendzick, N., Peress, N. S., Shandy, M. S., Slatkin, D. N., Tyson, G. W., and Wielopolski, L. Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery, 44: 1182-1192, 1999.
34. Padridge, W. M. Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain barrier. J. Neurochem., 28: 103-108, 1977.
35. Padridge, W. M. Brain metabolism. A perspective from the bloodbrain barrier. Physiol. Rev., 63: 1481-1535, 1983.
36. Smith, Q. R. The blood-brain barrier and the regulation of amino acid uptake and availability to brain. Adv. Exp. Med. Biol., 291: 55-71, 1991.
37. Smith, Q. R., Momma, S., Aoyagi, M., and Rapoport, S. I. Kinetics of neutral amino acid transport across the blood-brain barrier. J. Neurochem., 49: 1651-1658, 1987.
38. Crone, C. The permeability of capillaries in various organs as determined by use of the "indicator diffusion" method. Acta Physiol. Scand., 58: 292-305, 1963.